Taken together, several drugs that target ERBB2/HER2 and/or ERBB3/HER3, including small molecule inhibitors and antibodies, have shown evidence of pan-cancer activity in NRG1 fusion bearing malignancies. The gene discussed is ERBB2; the disease is cancer.